• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Myasthenia Gravis Companies

    ID: MRFR/HC/5800-CR
    200 Pages
    Rahul Gotadki
    December 2024

    Myasthenia gravis (MG) is a chronic, complex, autoimmune disorder that affects the neuromuscular junction and leads to varying degrees of muscle weakness and fatigue. There are several companies involved in research, development, and support related to Myasthenia Gravis.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Myasthenia Gravis Market Research Report – Global Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Myasthenia Gravis Market


    Myasthenia Gravis Key Companies*Disclaimer: List of key companies in no particular orderLatest Myasthenia gravis Companies Update


    • September 2023: Recipharm and Ahead Therapeutics formed a partnership to collaboratively develop a novel therapeutic intervention for myasthenia gravis, a rare autoimmune disorder. Ahead Therapeutics is a biotechnology company based in Spain that utilizes its proprietary technology to develop therapeutic interventions for a variety of autoimmune conditions. Recipharm will provide analytical and process development expertise to facilitate toxicological research, as well as Good Laboratory Practice (GLP) manufacturing of lipid nanoparticles for the encapsulation of the active pharmaceutical ingredient, namely an antigen peptide. Recipharm also offers the capacity to expand manufacturing operations to facilitate the future commercialization of the drug. By employing a biomimetic strategy, liposomes are able to induce antigen-specific immunological tolerance, thereby halting the autoimmune response.




    • September 2023: UCB, a prominent biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) had granted approval for two of its medications, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan). These medications have been approved for the treatment of generalized myasthenia gravis (gMG) in adult patients whose response to corticosteroids or other immunosuppressants has been inadequate. Japan has earned the distinction of being the first nation to simultaneously grant approval for rozanolixizumab and lucoplan. This means that for the first time, Japanese physicians and their patients will be able to choose between two novel targeted medications for the treatment of generalized myasthenia gravis (gMG) from a single pharmaceutical company, thereby providing unique options and adaptability. UCB is presented with an opportunity to provide personalized and ground-breaking benefits to adult patients in Japan who are afflicted with generalized myasthenia gravis (gMG) due to the company's prestigious group of Japanese medical and scientific professionals as well as its extensive background in the field of neurology.


    List of Myasthenia gravis Key companies in the market

    • GE Healthcare

    • Novartis AG

    • Boston Scientific Corporation

    • Grifols S.A.

    • Koninklijke Philips N.V.

    • Alexion Pharmaceuticals Inc.